MedTrace Logo

AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer

NCT06196697 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2024-06-27

No results posted yet for this study

Summary

The goal of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and anti-tumor activities of cadonilimab in combination with Ivonescimab plus chemotherapy as first-line therapy in adult subjects with HER2 negative、advanced or metastatic gastric (G) or gastroesophageal junction (GEJ) cancer.

Conditions

  • Gastric Adenocarcinoma
  • Gastroesophageal Junction Adenocarcinoma

Interventions

BIOLOGICAL

Cadonilimab

Subjects will receive AK104 by intravenous administration

BIOLOGICAL

Ivonescimab

Subjects will receive AK112 by intravenous administration

DRUG

XELOX

Subjects will receive AK104 and AK112 in combination with XELOX(oxaliplatin and capecitabine)

DRUG

SOX

Subjects will receive AK104 and AK112 in combination withSOX(oxaliplatin and Tegafur)

Sponsors & Collaborators

  • Harbin Medical University

    lead OTHER

Principal Investigators

  • yanqiao zhang, phD · Harbin Medical University Cancer Hosptital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-10
Primary Completion
2027-01-31
Completion
2027-03-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06196697 on ClinicalTrials.gov